johnson & johnson spravato

Johnson & Johnson Secures FDA Approval For Nasal Spray

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Hosted on MSN · 12h

FDA approves Spravato, first monotherapy nasal spray to treat depression

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,

Becker's Hospital Review · 24m

J&J approves 1st monotherapy for treatment-resistant depression

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.

FiercePharma21h

Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapy

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

31m

Johnson & Johnson Reports Q4, Full-Year 2024 Results with Revenue Growth

Supported by operational growth of 6.7%, Johnson & Johnson ( JNJ, Financials) reported a 5.3% rise in fourth-quarter revenues to $22.5 billion. With operational growth of 5.9% except for COVID-19 ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Johnson & Johnson Secures FDA Approval For Nasal Spray

Trending now